Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018

Executive Summary

India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.

Advertisement

Related Content

Will GMP Lapses Stall Biocon-Mylan’s Biosimilars Build-Up?
Will GMP Lapses Stall Biocon-Mylan’s Biosimilars Build-Up?
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel